Pakistan Pharmaceutical Manufacturers Association

Pakistan has a very vibrant and forward looking Pharma Industry. At the time of independence in 1947, there was hardly any pharma industry in the country. Today Pakistan has about 400 pharmaceutical manufacturing units including those operated by 25 multinationals present in the country. The Pakistan Pharmaceutical Industry meets around 70% of the country's demand of Finished Medicine. The domestic pharma market, in term of share market is almost evenly divided between the Nationals and the Multinationals. The National pharma industry has shown a progressive growth over the years, particularly over the last one decade. The industry has invested substantially to upgrade itself in the last few years and today the majority industry is following Good Manufacturing Practices (GMP), in accordance with the domestic as well as international Guidance. Currently the industry has the capacity to manufacture a variety of product ranging from simple pills to sophisticated Biotech, Oncology and Value Added Generic compounds.

>>More Detail...

Pakistan Pharmaceutical Manufacturers Association held a gathering to celebrate 60 years of Pharmaceutical Industry in Pakistan on August 28, 2008 at Lahore . Prime Minister Syed Yousaf Raza Gillani was the Chief Guest. The event was attended by Provincial ministers, Parliamentary Secretary of Health, industry entrepreneurs, professionals, officials of the Ministry of Health, other government officials and other prominent persons.

FACULTY OF PHARMACY UNIVERSITY OF SINDH

The Department of Pharmacy initially established in 1974, was upgraded to the Institute of Pharmacy in 1999 and finally became Faculty on 2nd May 2005. Earlier, it offered courses leading to the degree of B. Pharmacy (4- year courses). However as of 2004 session, nomenclature the of degree has been changed to Doctor of Pharmacy (Pharm D) and it has been made five years (10- semester) degree course. The Faculty also offers M.Phil/ Ph.D. in the fields of Pharmaceutics, Pharmaceutical Chemistry, Pharmacology and Pharmacognosy, while Pharm-D degree is offered in jointly by the four component departments. The faculty comprises skilled professionals.

The Faculty has to date produced about 1000 Pharmacists out of which more than 99% are working in different organizations of National and International repute. At present the Faculty has on its role 1000 local students and about 200 (Male & Female) students from more than 12 different countries and that gives a look of International gathering.

Its component departments are:-

i. Department of Pharmaceutical Chemistry

ii. Department of Pharmaceutics

iii. Department of Pharmacology

iv. Department of Pharmacognosy

IPTonline - The Pharmaceutical Technology Journal

IPTonline - An archive of published papers from Innovations in Pharmaceutical Technology.

This website is designed to keep you informed of the latest ideas, cutting-edge technologies and innovations shaping the future of pharmaceutical research, pharmaceutical development and pharmaceutical manufacturing.

Free to view, with only a nominal fee to print, the online pharmaceutical technology journal brings together the views and expertise of over 600 renowned technical specialists. Each editorial section includes commercial online innovation features and case-studies of technology in action, contributed by major industry suppliers. New product announcements and a calendar of pharmaceutical conferences and exhibitions ensure that you don’t miss out on the key events of the year.

Giant Pharma Companies Glaxo and Pfizer Merge to Develop AIDS Drugs

In a new agreement, giant pharmaceutical multinationals GlaxoSmithKline Plc and Pfizer Inc., the two leading developers of AIDS drugs, set up a joint company to develop drugs against HIV. This new company will hold nearly a fifth of the market for treatments against the virus. Glaxo will initially have an 85 percent stake in the joint venture. Pfizer will have the remaining 15 percent. Through the years, Glaxo has reflected a more dominant position in marketed products. Both companies admit, though, that this scenario is bound to change in the future.

The merger is yet another manifestation of an apparently increasing trend by big pharmaceutical manufacturers to collaborate in the cost-intensive and highly risky venture of drug development, with R&D occupying most of the cost and investment risks. Both companies expect that the union will enable them to build more sustainable and cost-effective processes in developing drugs.

’Join forces’ is the philosophy announced by the union of the two pharmaceutical giants. Their aim is to address competition from other firms in the lucrative market for antiretroviral drugs. The new company whose name will not be known until the union is complete before end of the year, will have a total of 11 drugs against the AIDS virus and another six under development. These represent 19% of the market. It is estimated that there are 33 million carriers worldwide, mostly in developing countries.

Multivitamins in pregnancy reduce risk of low birth weights

Prenatal multivitamin supplements are associated with a significantly reduced risk of babies with a low birth weight compared with prenatal iron-folic acid supplementation, found a new study in the Canadian Medical Association Journal (CMAJ) http://www.cmaj.ca/press/pgE99.pdf (www.cmaj.ca). The World Health Organization currently recommends iron-folic acid supplements for all pregnant women. Previous studies have not shown an advantage from prenatal multimicronutrient supplementation over iron-folic acid supplementation.

"Low birth weight and related complications are considered the most common cause of global infant mortality under the age of 5 years," write Dr. Prakash Shah and study coauthors from Mount Sinai Hospital in Toronto. "With the possibility of reducing low birth weight rates by 17%, micronutrients supplementation to pregnant women, we believe, offers the highest possible return for the investment. These results are synthesized findings from 15 studies published worldwide."

It is estimated that of the total 133 million births worldwide per year, 15.5% are low birth weight babies. The authors suggest that approximately 1.5 million babies born with a low birth weight could be avoided each year globally, if all mothers receive prenatal multimicronutrient supplementation.

The research is limited by variability among the included studies, including timing, duration, composition of micronutrients, and characteristics of the study populations.

In a related commentary http://www.cmaj.ca/press/pg1188.pdf, Dr. Zulfiqar Bhutta and Dr. Batool Azra Haider of the Aga Khan University in Karachi, Pakistan recommend that multimicronutrient supplementation during pregnancy replace iron and folate supplements in susceptible populations if it is proven safe and effective. They note that multiple interventions in developing countries may be necessary to improve maternal nutrition and fetal status such as fortified food supplements, interventions that address specific nutrient deficiencies, and measures to reduce the burden of HIV, malaria and other diseases.

Source: Canadian Medical Association Journal

Report warns of problems with multivitamins

NEW YORK (Reuters Health) - More than 30 percent of multivitamins tested recently by ConsumerLab.com contained significantly more or less of an ingredient than claimed, or were contaminated with lead, the company reports.

ConsumerLab.com, based in White Plains, New York, is privately held and provides consumer information and independent evaluations of products that affect health and nutrition. According to the company, it is neither owned by nor has a financial interest in any companies that make, distribute or sell consumer products.

Several multivitamin products tested, including three for children, exceeded tolerable upper limits established by the Institute of Medicine for ingredients such as vitamin A, folic acid, niacin and zinc, according to the report posted on www.ConsumerLab.com.

For example, the Institute of Medicine sets a recommended daily allowance (RDA) of 1,300 international units (IU) of vitamin A for children ages 4 to 8 years and an upper tolerable limit of 3,000 IU. However, one multivitamin tested provided 5,000 IU of vitamin A.

In the short term, too much vitamin A may cause nausea and blurred vision, and, in the long-term, may lead to bone softening and liver problems.

Upper tolerable limits for niacin and zinc were also exceeded by some of the supplements for young children tested. Excess niacin may cause skin tingling and flushing and high levels of zinc may cause immune deficiency and anemia.

Tests turned up problems with some men's multivitamin products as well. Two of three men's multivitamins failed to pass testing. One contained too much folic acid, which may increase the risk of prostate cancer, while another was contaminated with lead.

Among four women's multivitamins tested, one provided only 66 percent of its claimed vitamin A; one of five seniors' multivitamins selected contained only 44 percent of its vitamin A; and among three prenatal vitamins, one was short on vitamin A.

Two out of five general multivitamins were short on ingredients: one provided only 50 percent of its claimed folic acid and the other was missing 30 percent of its calcium.

A vitamin water tested by ConsumerLab.com had 15 times its stated amount of folic acid, so drinking one bottle would exceed the tolerable limit for adults; less than half a bottle would put children over the limit, the company warns on its website.

Multivitamin Medicine

To treat the vitamin deficiency in human body, we bring forth Multivitamin Medicine under the name Recxee-350. The Multivitamin Medicine is rich in vitamins line vitamin E and Vitamin C. These are effective enough yet free from side-effects. We rank top among the Multivitamin Capsules Manufacturers and Suppliers in India.

Note
These products are not intended to prevent, diagnosis, or cure any disease or symptomps of disease, but only for nutritional purpose.